mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for GLRX2
Gene summary
Basic gene Info.Gene symbolGLRX2
Gene nameglutaredoxin 2
CytomapUCSC genome browser: 1q31.2
Type of geneprotein-coding
DescriptionbA101E13.1 (GRX2 glutaredoxin (thioltransferase) 2)
Modification date20141207
dbXrefs MIM : 606820
Ensembl : ENSG00000023572
HPRD : 12112
Vega : OTTHUMG00000035677
ProteinUniProt: Q9NS18
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_GLRX2
BioGPS: 51022
PathwayNCI Pathway Interaction Database: GLRX2
Pathway Commons: GLRX2
ContextiHOP: GLRX2
ligand binding site mutation search in PubMed: GLRX2
UCL Cancer Institute: GLRX2
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0010033response to organic substance11397793
GO:0042542response to hydrogen peroxide11397793

Ligand binding site mutations for GLRX2
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for GLRX2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for GLRX2 from PDB

Differential gene expression and gene-gene network for GLRX2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of GLRX2 and the right PPI network was created from samples without mutations in the LBS of GLRX2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for GLRX2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for GLRX2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
Approved|nutraceuticalDB00143GlutathioneSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of GLRX2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of GLRX2
Multiple alignments for Q9NS18 in multiple species
LBSAA sequence# speciesSpecies
A134TFIGGATDTHR2Homo sapiens, Bos taurus
A134RFIGGAADTHR1Mus musculus
A134IFIGGAADTHR1Rattus norvegicus
C77FSKTSCSYCTM2Homo sapiens, Bos taurus
C77FSKTSCSYCSM1Mus musculus
C77FSKSSCSYCSM1Rattus norvegicus
G133GTFIGGATDTH2Homo sapiens, Bos taurus
G133GRFIGGAADTH1Mus musculus
G133GIFIGGAADTH1Rattus norvegicus
H88AKKIFHDMNVN2Mus musculus, Rattus norvegicus
H88AKKLFHDMNVN1Homo sapiens
K74VVIFSKTSCSY3Homo sapiens, Mus musculus, Bos taurus
K74VVIFSKSSCSY1Rattus norvegicus
K84YCSMAKKIFHD2Mus musculus, Rattus norvegicus
K84YCTMAKKLFHD1Homo sapiens
K85CSMAKKIFHDM2Mus musculus, Rattus norvegicus
K85CTMAKKLFHDM1Homo sapiens
P122GERTVPRIFVN4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
Q109YGNQFQDALYK1Homo sapiens
Q109YGNQFQDALHK1Mus musculus
Q109YGSQFQEALYK1Rattus norvegicus
Q109YGSQFQDALHK1Bos taurus
S76IFSKTSCSYCT2Homo sapiens, Bos taurus
S76IFSKTSCSYCS1Mus musculus
S76IFSKSSCSYCS1Rattus norvegicus
S78SKTSCSYCTMA2Homo sapiens, Bos taurus
S78SKTSCSYCSMA1Mus musculus
S78SKSSCSYCSMA1Rattus norvegicus
T120MTGERTVPRIF4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
T135FIGGATDTHRL2Homo sapiens, Bos taurus
T135FIGGAADTHRL2Mus musculus, Rattus norvegicus
V121TGERTVPRIFV4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
Y79KTSCSYCTMAK2Homo sapiens, Bos taurus
Y79KTSCSYCSMAK1Mus musculus
Y79KSSCSYCSMAK1Rattus norvegicus
Y94DMNVNYKVVEL3Homo sapiens, Rattus norvegicus, Bos taurus
Y94DMNVNYKAVEL1Mus musculus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas